BACKGROUND: Stress contributes to the development and maintenance of substance use disorders (SUD), with some research suggesting that the impact of stress on SUD is greater in women. However, this has yet to be evaluated in a national dataset, across major substances of abuse. METHODS: Using data from the newly available U.S. National Epidemiologic Survey on Alcohol and Related Conditions (NESARC; Wave 3; n=36,309) we evaluated relationships among past year stressful life events (0 or 1 vs. 2+ events, range 0-16) and gender, and their association with transitions (new vs. absent cases; ongoing vs. remitted cases) in Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) alcohol use disorder (AUD), tobacco use disorder (TUD), cannabis use disorder (CUD), and nonmedical prescription opioid use disorder (OUD) diagnoses. RESULTS: Having 2 or more stressful life events in the past year increased the odds of having a new AUD, TUD, CUD, and OUD (OR=3.14, 2.15, 5.52, and 3.06, respectively) or ongoing AUD, TUD, and CUD (OR=2.39, 2.62, and 2.95, respectively) compared to 0 or 1 stressful life event. A stress by gender interaction for new vs. absent AUD demonstrated that having 2 or more stressful life events was associated with increased odds of new AUD in men (OR=2.51) and even greater odds of new AUD in women (OR=3.94). CONCLUSIONS: Results highlight that stress is a robust factor in both men and women with new or ongoing substance use disorders, and that effective treatments for substance use should consider the role of stress in addiction etiology and maintenance. There was little evidence for gender differences in the role of stress on transitions in substance use disorders, except for the onset of alcohol use disorders. Given that rates of alcohol use disorders are increasing in women; the impact of stress needs to be considered.
BACKGROUND: Stress contributes to the development and maintenance of substance use disorders (SUD), with some research suggesting that the impact of stress on SUD is greater in women. However, this has yet to be evaluated in a national dataset, across major substances of abuse. METHODS: Using data from the newly available U.S. National Epidemiologic Survey on Alcohol and Related Conditions (NESARC; Wave 3; n=36,309) we evaluated relationships among past year stressful life events (0 or 1 vs. 2+ events, range 0-16) and gender, and their association with transitions (new vs. absent cases; ongoing vs. remitted cases) in Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) alcohol use disorder (AUD), tobacco use disorder (TUD), cannabis use disorder (CUD), and nonmedical prescription opioid use disorder (OUD) diagnoses. RESULTS: Having 2 or more stressful life events in the past year increased the odds of having a new AUD, TUD, CUD, and OUD (OR=3.14, 2.15, 5.52, and 3.06, respectively) or ongoing AUD, TUD, and CUD (OR=2.39, 2.62, and 2.95, respectively) compared to 0 or 1 stressful life event. A stress by gender interaction for new vs. absent AUD demonstrated that having 2 or more stressful life events was associated with increased odds of new AUD in men (OR=2.51) and even greater odds of new AUD in women (OR=3.94). CONCLUSIONS: Results highlight that stress is a robust factor in both men and women with new or ongoing substance use disorders, and that effective treatments for substance use should consider the role of stress in addiction etiology and maintenance. There was little evidence for gender differences in the role of stress on transitions in substance use disorders, except for the onset of alcohol use disorders. Given that rates of alcohol use disorders are increasing in women; the impact of stress needs to be considered.
Entities:
Keywords:
alcohol; cannabis; gender; opioid; stress; substance use disorders; tobacco
Authors: Sherry A McKee; Rajita Sinha; Andrea H Weinberger; Mehmet Sofuoglu; Emily L R Harrison; Meaghan Lavery; Jesse Wanzer Journal: J Psychopharmacol Date: 2010-09-03 Impact factor: 4.153
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: A D Lê; Douglas Funk; Walter Juzytsch; Kathleen Coen; Brittany M Navarre; Carlo Cifani; Yavin Shaham Journal: Psychopharmacology (Berl) Date: 2011-02-12 Impact factor: 4.530
Authors: Helen C Fox; Dongju Seo; Keri Tuit; Julie Hansen; Anne Kimmerling; Peter T Morgan; Rajita Sinha Journal: J Psychopharmacol Date: 2012-01-09 Impact factor: 4.153
Authors: Sarah Bowen; Neharika Chawla; Susan E Collins; Katie Witkiewitz; Sharon Hsu; Joel Grow; Seema Clifasefi; Michelle Garner; Anne Douglass; Mary E Larimer; Alan Marlatt Journal: Subst Abus Date: 2009 Oct-Dec Impact factor: 3.716
Authors: Bridget F Grant; Tulshi D Saha; W June Ruan; Risë B Goldstein; S Patricia Chou; Jeesun Jung; Haitao Zhang; Sharon M Smith; Roger P Pickering; Boji Huang; Deborah S Hasin Journal: JAMA Psychiatry Date: 2016-01 Impact factor: 21.596
Authors: MacKenzie R Peltier; Terril L Verplaetse; Yann S Mineur; Ralitza Gueorguieva; Ismene Petrakis; Kelly P Cosgrove; Marina R Picciotto; Sherry A McKee Journal: Neuropharmacology Date: 2021-02-16 Impact factor: 5.250
Authors: Terril L Verplaetse; MacKenzie R Peltier; Walter Roberts; Brian Pittman; Sherry A McKee Journal: Addict Behav Date: 2021-01-06 Impact factor: 3.913